Libre Duo devices become the first glucose-ketone monitors approved for diabetes care, offering real-time alerts for diabetic ketoacidosis risk
The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
The Establishment Inspection Report came following closure of a product- specific pre-approval inspection from March 2 to March 7, 2026
The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
The decision clears the drug as a monotherapy for adults with unresectable, locally advanced or metastatic non-small cell lung cancer
A one-shot gene-editing cholesterol therapy could soon be a reality
The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients
AAV vectors are widely used in gene therapy for their strong therapeutic potential
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
Subscribe To Our Newsletter & Stay Updated
